Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma

Özkan, Hasan; Erdal, Harun; Koçak, Erdem; Tutkak, Hüseyin; Karaeren, Zihni; Yakut, Mustafa; Köklü, Seyfettin

doi:10.1002/jcla.20484

Cited by 51 publications

(38 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ozkan H,et al had recently reported that the sensitivity, specificity, and positive and negative predictive values of serum GPC3 was 61.33%, 41.82%, 58.97%, and 44.43%, respectively. It is suggested that serum GPC3 is not a useful diagnostic and prognostic marker for HCC 32 . However, in this study, it is firstly reported that the GPC3L expression was detected in 77.4% of patients with serum AFP negative and in 81.2% of patients with AFP greater or equal to 400µg/L.…”

Section: Resultsmentioning

confidence: 99%

Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients

Li¹,

Liu²,

Shang³

et al. 2013

Afr H. Sci.

View full text Add to dashboard Cite

Background: The prognosis of patients with hepatocellular carcinoma(HCC) is generally very poor with a 5-year survival rate of less than 15% since most of them are diagnosed clinically at their late stage.However,the differential diagnosis between alpha fetoprotein(AFP) negative HCC and cirrhotic nodules is still difficult. Objectives: To evaluate the diagnostic value of glypican-3(GPC3) in patients with AFP negative hepatitis B related HCC. Methods The liver tissue GPC3 (GPC3L) expression was tested from 426 for surgery and 179 of needle biopsies of hepatitis B related HCC patients using immunohistochemistry staining. Serum GPC3 (GPC3S) and AFP were also measured. Results Among surgical HCC samples, 80.0% of GPC3L expression was positive, however, in paracarcinomatous and cirrhotic nodules were negative. In needle biopsy tissues, GPC3L positively expression was in 74.9%. The sensitivity of AFP>400µg/L was 25.4%. The GPC3S >3.5µg/L was determined as a positive. The area of ROC curve of GPC3S was 0.68(95% CI 0.56-0.79,P<0.05) in all HCC patients,0.81 (95% CI 0.62 -0. 98, P<0.05) in AFP greater or equal to 400µg/L and 0.64 (95% CI 0.51-0.77, P=0.051) in AFP negative patients. The GPC3S was positive in 48.8% of patients with AFP negative. No difference was observed between GPC3L/GPC3S and serum AFP. Conclusions GPC3 may be helpful in improving diagnosis of HCC and in differentiating diagnosis between AFP negative HCC and cirrhotic nodules.

show abstract

Section: Resultsmentioning

confidence: 99%

Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients

Li¹,

Liu²,

Shang³

et al. 2013

Afr H. Sci.

View full text Add to dashboard Cite

show abstract

“…Therefore, glypicans play an important role in growth factor-mediated signal transduction and it is not surprising that they are expressed in tumoral microenvironments (14). In addition, since glypicans mediate the formation of cell-cell and cell-extracellular matrix adhesions, they exert pro-as well as anti-tumorigenic effects (15)(16)(17)(18)(19)(20).…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic significance of glypican 5 and glypican 6 gene expression levels in gastric adenocarcinoma

Dinccelik-Aslan

Gümüş-Akay

Elhan

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Gastric cancer is one of the most common malignancies worldwide and the second most common cause of cancer-related mortality. Previous studies revealed several genetic alterations specific to gastric cancer. In this study, we aimed to investigate the diagnostic and prognostic significance of the expression levels of the glypican 5 and glypican 6 genes (GPC5 and GPC6, respectively) in gastric cancer. For this purpose, GPC5 and GPC6 expression was quantitatively determined by quantitative polymerase chain reaction method in normal gastric mucosa and intestinal type gastric adenocarcinoma samples from 35 patients. The expression levels of GPC5 and GPC6 were compared between normal and tumor tissues. Additionally, the association of the expression levels in tumor tissues with several clinicopathological parameters was evaluated. Although GPC5 was not expressed in any of the samples, the expression of GPC6, which was detected in both groups, was found to be significantly higher in tumor tissues compared to that in normal samples (P=0.039). However, there was no statistically significant association between GPC6 expression and any of the clinicopathological parameters investigated (P>0.05). Our findings suggested that an increase in GPC6 expression levels may be implicated in gastric cancer development, but not in cancer progression.

show abstract

“…Tangkijvanich et al reported that GPC3 and AFP combination yielded 78 % sensitivity [37]. Ozkan et al reported that the sensitivity of GPC3 and AFP combination does not exceed 67 % [13]. Fig.…”

Section: Discussionmentioning

confidence: 95%

“…In contrast to the hepatocytes of healthy individuals and hepatitis patients, many studies reported an increased GPC3 expression in HCC tissues [9]. However, many studies suggested that serum GPC3 is a specific HCC biomarker owing to its higher levels in HCC than that in healthy or hepatitis individuals [10,11]; conflicting results were obtained by other studies [12][13][14]. There is an agreement between most of these studies and others that GPC3 alone is not a promising HCC serum maker.…”

Section: Introductionmentioning

confidence: 91%

GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma

et al. 2016

View full text Add to dashboard Cite

Conflicting results for circulating glypican-3 (GPC3) were reported in hepatocellular carcinoma (HCC) diagnosis. We aimed to improve the diagnostic power of GPC3 by developing a GPC-HCC model for diagnosing HCC. GPC3 was tested for HCC (138), liver cirrhosis (56), and fibrosis (62) patients by ELISA. Data from patient groups were retrospectively analyzed. A novel score, GPC-HCC, based on combination of GPC3 and routine laboratory tests, was developed for HCC diagnosis. The GPC-HCC model values produced a significant 1.7-fold increase in liver cirrhosis and 3.2-fold increase in HCC, in comparison with liver fibrosis. In contrast to GPC3 and alpha fetoprotein (AFP), the GPC-HCC model showed high HCC diagnostic power with area under the curve (AUC) of 0.939, sensitivity 93 %, specificity 93 %, positive predictive value 89 %, negative predictive value 95 %, and efficiency 93 %. GPC-HCC AUC in HCC with single tumor, absent vascular invasion, and tumor size ≤3 cm were 0.93, 0.92, and 0.92, respectively, compared with 0.63, 0.63, and 0.64, respectively, for GPC3 and 0.69, 0.70, 0.55, respectively, for AFP. In conclusion, owing to these promising findings, the combination of GPC3 with other laboratory simple routine tests (GPC-HCC model) could improve the diagnostic power of GPC3 in HCC screening and follow up of cirrhotic patients.

show abstract

Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma

Cited by 51 publications

References 17 publications

Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients

Diagnostic value of glypican-3 in alpha fetoprotein negative hepatocellular carcinoma patients

Diagnostic and prognostic significance of glypican 5 and glypican 6 gene expression levels in gastric adenocarcinoma

GPC-HCC model: a combination of glybican-3 with other routine parameters improves the diagnostic efficacy in hepatocellular carcinoma

Contact Info

Product

Resources

About